Answers are grounded in this paper and cite their sources.
The primary objective of this research is to develop a highly stable, biocompatible nanocomposite for pH-responsive, controlled delivery of 5-fluorouracil (5-FU) to enhance its therapeutic performance. In this study, a carboxymethyl cellulose (CMC)/ riboflavin (RF) /carbon nanotubes (CNTs)-based nanocomposite was synthesized using the water/oil/water (W/O/W) double emulsion method with the aid of sweet almond oil and the surfactant Span 80, for controlled delivery of the drug 5-FU. Fourier-transform infrared spectroscopy (FTIR) was used to examine the functional groups of the nanocomposite components, and X-ray diffraction (XRD) was used to study the crystal structure. To determine the morphology, a field-emission scanning electron microscope (FE-SEM) was used, which confirmed the core-shell structure of the nanocarriers with a hemispherical shape. Dynamic light scattering (DLS) was used to determine the particle size, which was reported to be 236.7 nm. Analysis of zeta potential showed a value of −89.77 ± 3.20 mV, indicating a highly stable colloidal structure. The drug loading efficiency (LE) was 45.25%, and the encapsulation efficiency (EE) was 87%. Over a 96-hour period, the drug-loaded nanocarrier exhibited a strictly pH-dependent behavior, with cumulative drug release reaching a maximum of 91% in the acidic tumor environment (pH 5.4) versus 75% in the neutral healthy tissue medium (pH 7.4). The drug release mechanism was investigated by fitting experimental data to different kinetic models. The release patterns of 5-FU in the nanocomposite under neutral and acidic conditions followed the Hixson-Crowell ( 𝑅 2 = 0 . 9 9 7 2 ) and Korsmeyer–Peppas ( 𝑅 2 = 0 . 9 6 1 9 ) kinetic models, respectively. The MTT assay was performed to assess cell viability and cytotoxicity, revealing that the CNTs/CMC/RF@5-FU nanocarrier exhibited significant cytotoxicity against breast cancer cells, successfully reducing MCF-7 cell viability to 35.45% compared to 50.51% for the free drug.
No takes yet. Share an insight, caveat, or question.
Momeni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: